Core Viewpoint - Haofan Bio (301393.SZ) is currently experiencing a decline in stock price, trading at 59.05 yuan with a drop of 4.28%, resulting in a total market capitalization of 6.377 billion yuan [1] Group 1: IPO Details - Haofan Bio was listed on the Shenzhen Stock Exchange's ChiNext board on July 12, 2023, with an initial public offering (IPO) of 27 million shares at a price of 67.68 yuan per share [1] - The total amount raised from the IPO was 1.82736 billion yuan, with a net amount of 1.6553887 billion yuan after deducting issuance costs [1] - The net amount raised exceeded the original plan by 510.3887 million yuan, which was initially set at 1.145 billion yuan [1] Group 2: Fund Utilization - The funds raised are intended for several projects, including the development and production of 100kg/year peptide and protein reagents, construction of a headquarters, and a project for producing 1,002 tons of peptide reagents and pharmaceutical intermediates [1] - Additional allocations include the establishment of a research platform for peptides and protein reagents and supplementing working capital [1] Group 3: Issuance Costs - The total issuance costs for the IPO amounted to 171.9713 million yuan, with underwriting and sponsorship fees accounting for 146.1888 million yuan [1]